Cell therapy in surgical treatment of fistulas. Preliminary results

• DOI: 10.5604/01.3001.0010.1019
• Publication Date: 2018-05-22T05:25:04Z
• Authors: Marcin Piejko; Michał Romaniszyn; Julia Borowczyk-M...; Justyna Drukała; Piotr Wałęga
• Keywords: Rectovaginal Fistula; Fecal Incontinence

Risk of recurrence after surgical treatment a recurrent fistula is up to 50%. It has be known that more aggressive associated with high risk anal sphincter damage and leads incontinence. Several studies have been designed elaborate minimally invasive rectovaginal fistulas. The properties Adipose-derived Stem Cells (ASC) significantly enhance natural healing potency. Here, we present our experience combined cell therapy in the fistulas.Four patients were enrolled study unsuccessful treatments past - 1-3 fistulas including two women graciloplasty, patient 4 male complex perianal fistula. Adipose tissue was obtained from subcutaneous tissue. ASCs isolated, cultured 10+/-2 mln cells injected into walls Follow-up physical examination anoscopy performed at 1, 4, 8, 12 weeks, 6 months implantation.Up 8 weeks ASC implantation, symptoms fistulas' tracts disappeared. At 1-3, communication between vaginal rectal openings closed 12-16 w. intestinal continuity restored 3 4. After 6-month follow-up, tract closed. Up m. implantation no recurrences or adverse events observed.ASCs pre-treated used four patients. All them healed. This encouraging result needs further trials evaluate clinical efficiency cost-effectiveness ratio.